@article{4023e380026f4e12b6c334490fbbc9e3,
title = "ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer",
abstract = "Our study demonstrates that microRNA-22-3p (miR-22-3p) acts as a tumor suppressor in which its expression is markedly reduced in TNBC tumors. Restoration of its expression by miR-22-3p nanotherapy suppress tumor growth and progression by directly inhibiting of eEF2K-PI3K/AKT and Src signaling. miR-22-3p-based RNA therapy may be novel treatment for TNBC.",
keywords = "Akt, EF2K, PI3K, Src, breast cancer, eEF2K, gene regulation, gene silencing, liposomes, miR-22, nanoparticles, therapy, triple-negative breast cancer, tumor suppressor",
author = "Aysegul Gorur and Recep Bayraktar and Cristina Ivan and Mokhlis, {Hamada Ahmed} and Emine Bayraktar and Nermin Kahraman and Didem Karakas and Selda Karamil and Kabil, {Nashwa N.} and Pinar Kanlikilicer and Burcu Aslan and Lulufer Tamer and Zhihui Wang and Vittorio Cristini and Gabriel Lopez-Berestein and George Calin and Bulent Ozpolat",
note = "Funding Information: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors. The studies described herein were supported by the MD Anderson Center for RNA Interference and Non-Coding RNA; NIH/NCI under award number P30CA016672 using the NIH/NCATS grant UH3TR00943-01 through the NIH Common Fund; and Office of Strategic Coordination. G.C. is the Felix L. Haas Endowed Professor in Basic Science and is supported by NCI grants 1R01 CA182905-01 and 1R01 CA222007-01A1, an NIGMS 1R01 GM122775-01 grant, U54 grants CA096297/CA096300, a University of Puerto Rico/MD Anderson Partnership for Excellence in Cancer Research 2016 Pilot Project, a Team DOD (CA160445P1) grant, a Sister Institution Network Fund 2017 grant, and the Estate of C.G. Johnson, Jr., A.G. and B.O. conceived and coordinated the study and wrote the manuscript. R.B. and P.K. performed the luciferase assay and prepared figures. C.I. analyzed overall survival. B.O. and N.K. prepared nanoliposomal particles incorporating miRNAs and performed in vivo animal studies. E.B. and D.K. performed immunohistochemical analysis of in vivo tissue samples and contributed to preparation of figures. H.A.M. S.K. N.N.K. and B.A. provided technical assistance. Z.W. and V.C. performed mathematical remodeling of miR-22-3p and control miRNA for TNBC tumors of MDA-MB-231 and MDA-MB-436. G.L.B. G.C. and L.T. contributed to writing the manuscript. All authors analyzed the results and approved the final version of the manuscript. The authors declare no competing interests. Funding Information: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors. The studies described herein were supported by the MD Anderson Center for RNA Interference and Non-Coding RNA ; NIH/NCI under award number P30CA016672 using the NIH/NCATS grant UH3TR00943-01 through the NIH Common Fund ; and Office of Strategic Coordination . G.C. is the Felix L. Haas Endowed Professor in Basic Science and is supported by NCI grants 1R01 CA182905-01 and 1R01 CA222007-01A1 , an NIGMS 1R01 GM122775-01 grant, U54 grants CA096297 / CA096300 , a University of Puerto Rico /MD Anderson Partnership for Excellence in Cancer Research 2016 Pilot Project, a Team DOD ( CA160445P1 ) grant, a Sister Institution Network Fund 2017 grant, and the Estate of C.G. Johnson, Jr. Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = mar,
day = "5",
doi = "10.1016/j.omtn.2021.01.016",
language = "English (US)",
volume = "23",
pages = "930--943",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",
}